A Phase-I/II Randomized Trial of Maintenance Vaccination Combined With Oral Metronomic Cyclophosphamide With or Without Adoptive Transfer of Vaccine-Primed CD3/CD28-CoStimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Dendritic Cell Vaccine
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 04 May 2017
At a glance
- Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary) ; Cyclophosphamide
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 12 Aug 2009 Planned end date changed from 1 Mar 2010 to 1 Mar 2013 as reported by ClinicalTrials.gov.